Short Interest in CeriBell, Inc. (NASDAQ:CBLL) Decreases By 13.8%

CeriBell, Inc. (NASDAQ:CBLL) was the target of a significant decrease in short interest in the month of March. As of March 13th, there was short interest totaling 1,659,720 shares, a decrease of 13.8% from the February 26th total of 1,925,021 shares. Currently, 5.5% of the shares of the stock are sold short. Based on an average trading volume of 318,243 shares, the short-interest ratio is presently 5.2 days.

Analysts Set New Price Targets

Several brokerages recently commented on CBLL. TD Cowen reiterated a “buy” rating on shares of CeriBell in a research report on Tuesday, December 9th. BTIG Research restated a “buy” rating and set a $30.00 price target on shares of CeriBell in a report on Wednesday, January 28th. Finally, Canaccord Genuity Group boosted their price objective on shares of CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $24.67.

CeriBell Price Performance

CBLL stock opened at $18.50 on Thursday. CeriBell has a 1 year low of $10.01 and a 1 year high of $24.33. The business’s 50-day moving average is $19.47 and its two-hundred day moving average is $17.36. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.73 and a quick ratio of 9.35. The firm has a market capitalization of $696.34 million, a P/E ratio of -12.58 and a beta of 0.93.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.07. The company had revenue of $24.78 million during the quarter, compared to analysts’ expectations of $23.95 million. CeriBell had a negative net margin of 59.97% and a negative return on equity of 31.77%. Analysts anticipate that CeriBell will post -2.46 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Xingjuan Chao sold 79,000 shares of the company’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $21.27, for a total value of $1,680,330.00. Following the completion of the transaction, the chief executive officer owned 741,248 shares of the company’s stock, valued at approximately $15,766,344.96. This represents a 9.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP David Foehr sold 5,556 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $20.00, for a total value of $111,120.00. Following the transaction, the vice president owned 18,900 shares in the company, valued at $378,000. This trade represents a 22.72% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 203,627 shares of company stock worth $4,156,660 in the last ninety days. 20.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On CeriBell

Several large investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp boosted its position in shares of CeriBell by 1,945.9% in the 4th quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock valued at $26,797,000 after purchasing an additional 1,162,200 shares during the period. KCM Capital Inc acquired a new position in shares of CeriBell during the fourth quarter worth about $21,930,000. Royce & Associates LP acquired a new position in CeriBell during the 4th quarter worth approximately $11,695,000. Adage Capital Partners GP L.L.C. purchased a new position in CeriBell in the fourth quarter worth $10,965,000. Finally, CenterBook Partners LP increased its holdings in shares of CeriBell by 448.0% in the 3rd quarter. CenterBook Partners LP now owns 476,554 shares of the company’s stock valued at $5,476,000 after purchasing an additional 389,584 shares in the last quarter.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.